JNJ-61393215

JNJ-61393215

JNJ-61393215 is an experimental drug currently under development by Janssen Pharmaceutica, a pharmaceutical company that is part of the Johnson & Johnson family of companies. JNJ-61393215 is being investigated for its potential use in the treatment of insomnia and other sleep disorders.

History

JNJ-61393215 was first synthesized by researchers at Janssen Pharmaceutica as part of their ongoing efforts to develop new treatments for sleep disorders. The compound is part of a class of drugs known as orexin receptor antagonists, which work by blocking the action of orexin, a neurotransmitter that plays a key role in regulating sleep and wakefulness.

Mechanism of Action

JNJ-61393215 is a dual orexin receptor antagonist (DORA). It works by binding to the orexin receptors in the brain, thereby inhibiting the action of orexin. This results in a decrease in wakefulness and an increase in sleep. This mechanism of action is different from that of traditional sleeping pills, which typically work by enhancing the action of GABA, the main inhibitory neurotransmitter in the brain.

Clinical Trials

As of the time of writing, JNJ-61393215 is in the early stages of clinical development. Preliminary results from Phase I clinical trials have shown that the drug is well-tolerated and has a favorable safety profile. Further studies are needed to confirm these findings and to determine the drug's efficacy in treating insomnia and other sleep disorders.

Potential Applications

If approved, JNJ-61393215 could represent a new treatment option for individuals suffering from insomnia and other sleep disorders. The drug's unique mechanism of action could make it a valuable addition to the current arsenal of treatments for these conditions.

See Also

• Orexin receptor antagonist
• Insomnia
• Sleep disorders
• Janssen Pharmaceutica
• Johnson & Johnson